The end of the COVID-19 pandemic will come with the development of a safe and effective vaccine, a process experts say will take at least 12 to 18 months. Last week, however, the U.S. Department of Health and Human Services (HHS) blew that timeline out of the water, announcing that it would pay British drugmaker AstraZeneca upwards of $1 billion for 300 million doses of an experimental vaccine, which will start to become available as early as this October. AstraZeneca CEO Pascal Soriot was even more bullish, telling CNN, “We will start getting substantial doses by September, October,” and that “lots and lots of people will be able to be vaccinated before the end of the year.” At that pace, Soriot confirmed, the entire U.S. and U.K. populations could be vaccinated by early 2021.
Soriot cautioned that the vaccine’s delivery depends on its successful completion of human trials—“It has to work,” he told CNN. But he said AstraZeneca was on target to prove that it will through an accelerated testing schedule. To date, the vaccine has been tested on monkeys and a small group of human volunteers, with recruitment for a 10,260-subject study currently underway.
To begin mass inoculations against COVID in the month before the election would be a massive achievement for the Trump administration, which has seen its prospects for a second term dwindle with the lockdown caused by the coronavirus and its resultant economic carnage. According to reporting by Vanity Fair’s Gabriel Sherman, Donald Trump has privately expressed the belief that a COVID-19 vaccine would be ready within months.